The Role of MSH2/EPCAM: Urothelial Carcinoma Risk in Lynch Syndrome

The Role of MSH2/EPCAM: Urothelial Carcinoma Risk in Lynch Syndrome

Lynch syndrome (LS) is a hereditary cancer predisposition syndrome primarily associated with colorectal and endometrial cancers. However, its clinical spectrum extends beyond these malignancies, with urothelial carcinoma (UC), particularly upper tract urothelial carcinoma (UTUC), representing an important extracolonic manifestation.

Although the association between Lynch syndrome and urothelial cancer has been recognized for years, questions remain about the contribution of genetic and clinical factors to cancer risk and how these malignancies present. This is particularly relevant because urothelial cancer risk differs according to the underlying genotype.

A large German multicenter study has examined the clinical characteristics, genetic associations, and molecular features of urothelial carcinoma in patients with genetically confirmed Lynch syndrome, providing further evidence to inform future research on risk-adapted surveillance strategies.

The study, titled “Urothelial Carcinoma in Lynch Syndrome: Clinical and Molecular Insights From a Large Multicenter Cohort,” was published on November 13, 2026, in JCO Precision Oncology.

The research was conducted by Antonia Schuler, Christoph Engel, Aysel Ahadova, Katrin van Beekum, Stefan Aretz, Guido Fechner, Niklas Klümper, Nina Nelius, Emin Gashi, Hugo Montemont, Deepak B. Vangala, Diana Le Duc, Silke Redler, Andreas Block, Tim Ripperger, Alexander Link, Elke Holinski-Feder, Verena Steinke-Lange, Christopher Schroeder, Reiner Siebert, Jacob Nattermann, Matthias Kloor, and Robert Hüneburg, on behalf of the German Consortium for Familial Intestinal Cancer.

About the Study

Investigators retrospectively analyzed data from 3,274 adults with genetically confirmed Lynch syndrome enrolled in the nationwide registry of the German Consortium for Familial Intestinal Cancer. The study included carriers of pathogenic or likely pathogenic germline variants in MLH1, MSH2, MSH6, and PMS2, as well as deletions involving the 3′ end of EPCAM. Urothelial cancer diagnoses were identified through registry records and subsequently validated using available clinical and pathological information.

The analysis focused on the frequency and presentation of urothelial cancer, tumor location, the occurrence of multiple primary malignancies, and the association between genotype and cancer risk. Available tumor samples were also evaluated using MMR immunohistochemistry and microsatellite instability (MSI) testing.

Urothelial Carcinoma-HER

What Did the Study Find?

Among the 3,274 individuals with Lynch syndrome, 144 patients (4.4%) were diagnosed with urothelial carcinoma, accounting for a total of 224 primary tumors. The median age at first UC diagnosis was 55 years, ranging from 22 to 79 years. Upper tract tumors represented a substantial proportion of cases. Among 202 tumors with a known anatomical location, 114 (56.4%) were located in the upper urinary tract, while 88 (43.6%) arose in the bladder.

One important finding was that urothelial carcinoma represented the first documented malignancy in 50 patients (34.7%). These individuals were diagnosed at a median age of 49.5 years, and 82% carried an MSH2 pathogenic variant. This observation is clinically relevant because urothelial cancer may be the first malignancy diagnosed in individuals with Lynch syndrome, even without a previous history of colorectal or endometrial cancer.

Multiple primary urothelial malignancies were also documented. Metachronous tumors, diagnosed at distinct anatomical sites more than six months apart, occurred in 23 patients (16.0%), while five patients (3.5%) developed synchronous primary tumors.

MSH2/EPCAM Status Was Strongly Associated With Urothelial Cancer Risk

Genetic analysis showed a marked predominance of MSH2 pathogenic variants among affected patients. Of the 144 individuals diagnosed with urothelial cancer, 111 (77.1%) carried an MSH2 variant, compared with 22 (15.3%) carrying MLH1 and 11 (7.6%) carrying MSH6 variants. No urothelial cancer cases were documented among PMS2 carriers in this cohort.

Within the overall registry, urothelial carcinoma was documented in 8.1% of MSH2 carriers, compared with 1.9% of MLH1 and 2.3% of MSH6 carriers. In multivariable analysis, MSH2/EPCAM carrier status was independently associated with urothelial cancer risk compared with the MLH1/MSH6/PMS2 group.

The association was particularly pronounced for upper tract urothelial carcinoma, with an adjusted hazard ratio (HR) of 6.38 (95% CI 3.42–11.92; P < 0.001). For overall urothelial carcinoma, the HR was 4.43 (95% CI 2.85–6.89; P < 0.001), while for bladder cancer it was 2.88 (95% CI 1.59–5.22; P < 0.001). The combined upper tract and bladder cancer endpoint also showed a significant association (HR 4.01; 95% CI 2.57–6.27; P < 0.001).

Interestingly, neither a previous diagnosis of colorectal cancer nor a family history of urothelial carcinoma was independently associated with UC risk after adjustment for other clinical and genetic factors.

urothelial carcinoma

How Were These Cancers Diagnosed?

The investigators also examined the circumstances leading to urothelial cancer diagnosis, with information available for 109 patients. Of these, 26 (23.9%) presented with urinary tract-related symptoms, including gross hematuria in 17 patients and nonspecific urinary or irritative symptoms in nine. Another 28 patients (25.7%) had other or incompletely documented symptom-based presentations.

Another 20 patients (18.3%) were diagnosed incidentally during imaging or surgery performed for unrelated reasons, while 11 (10.1%) were diagnosed during urologic or oncologic surveillance. In 24 patients (22.0%), the indication for a preceding medical examination could not be classified more precisely. Diagnostic circumstances were unavailable for 35 of the 144 UC patients.

The diversity of these presentations highlights an important consideration for clinical practice: urothelial cancer in Lynch syndrome is not always detected through characteristic urinary symptoms. However, these retrospective findings do not establish the effectiveness of any particular screening approach.

Molecular Findings

Beyond the clinical characteristics, the investigators analyzed 31 urothelial cancer lesions from 18 patients to evaluate their molecular features. The results demonstrated a high prevalence of mismatch repair abnormalities. MMR deficiency was identified in 29 of 31 lesions (93.6%), while 30 lesions (96.8%) were MSI-high.

All 18 patients had at least one MMR-deficient tumor and at least one MSI-high tumor. Loss of MSH2 expression was observed in tumors from 14 patients, while MLH1 and MSH6 loss were identified in tumors from three and one patient, respectively.

These findings are consistent with the molecular characteristics of Lynch syndrome-associated malignancies and reinforce the relevance of MMR and MSI evaluation in urothelial tumors with clinical or genetic features suggestive of the syndrome. However, molecular testing was performed in a relatively small subset of patients, and the findings cannot be generalized to all urothelial cancers or used to determine the diagnostic performance of universal MMR/MSI testing.

Find more videos on OncoDaily YouTube TV.

What Do These Findings Mean for Clinical Practice?

The study adds important clinical and molecular information to the existing evidence on Lynch syndrome-associated urothelial carcinoma. In particular, the strong association between MSH2/EPCAM carrier status and urothelial cancer risk suggests that genotype should be considered when developing and evaluating future surveillance strategies.

The observation that urothelial cancer was the first documented malignancy in approximately one-third of affected patients is also relevant when considering Lynch syndrome in patients presenting with upper tract urothelial carcinoma or selected bladder cancers.

Nevertheless, several limitations should be considered. The retrospective registry-based design resulted in incomplete clinical information, surveillance practices were not standardized, and molecular analysis was restricted to a small number of available tumor samples. Reliable overall and cancer-specific survival estimates could not be obtained.

Importantly, while the findings support further investigation of genotype-adapted surveillance, the study did not evaluate whether a specific screening strategy improves early detection or clinical outcomes.

Takeaway

This large German multicenter study further defines the clinical and molecular characteristics of urothelial carcinoma in Lynch syndrome, demonstrating a strong association with MSH2/EPCAM carrier status, frequent upper urinary tract involvement, and a high prevalence of dMMR/MSI-high tumors among the samples analyzed.

The finding that urothelial carcinoma was the first documented malignancy in approximately one-third of affected patients is particularly relevant for recognizing Lynch syndrome beyond its more commonly associated cancers. These results provide a rationale for prospective studies of genotype-adapted surveillance, particularly among MSH2/EPCAM carriers, but do not yet establish an optimal screening strategy.

The original study is available in JCO Precision Oncology. 

Aharon Tsaturyan
Fact checked by Aharon Tsaturyan MD, Medical Writer
Amalya Sargsyan
Medically reviewed by Amalya Sargsyan MD, Medical Oncologist